the aid library

LIST OPTIONS

Filter

3012

Download (1084)

View PDF (1016)

GUIDELINES FOR CONDUCTING CLINICAL TRIALS OF MEDICINES, FOOD SUPPLEMENTS, VACCINES AND MEDICAL DEVICES IN GHANA

Food and Drugs Authority (FDA), Ghana (2013) C1

Document No. : FDA/SMC/CTD/GL-CCT/2013/01

Download (450)

View PDF (1171)

Guidelines for conduct of clinical trials in Kenya

Pharmacy and Poisons Board, Ministry of Health, Kenya (2016) C1

Download (2976)

View PDF (1165)

GUIDELINES FOR GOOD CLINICAL TRIAL PRACTICE IN ZIMBABWE

Medicines Control Authority of Zimbabwe (MCAZ) (2012) C2

Download (477)

View PDF (1648)

Guidelines for Cunducting Clinical Trials of Medicines, Food Supplements, Vaccines, and Medical Devices in Sierra Leone

Pharmacy Board Sierra Leone (2014) C1

Download (645)

View PDF (699)

Sierra Leone: Guidelines for Conducting Clinical Trials of Medicinal Products and Vaccines

Pharmacy Board Sierra Leone (2014) C1

Download (533)

View PDF (1037)

Zambia: GUIDELINES ON REGULATING THE CONDUCT OF CLINICAL TRIAL IN HUMAN PARTICIPANTS

Zambia Medicines Regulatory Authority (ZAMRA) (2016) C2

First Edition

Download (549)

View PDF (1089)

Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products Bangladesh

Directorate General of Drug Administration,, Ministry of Health and Family Welfare, People's Republic of Bangladesh (2015) C1

Guideline for Application to conduct Clinical Trials in Liberia

Liberia Medicines and Health Products Regulatory Authority (LMHRA) (2014) C1

Download (265)

View PDF (460)

Guidelines for laboratory and field testing of molluscicides for control of schistosomiasis

World Health Organization WHO (2019) C_WHO

This document provides up-to-date guidance on laboratory studies as well as smallscale (semi-field) and large-scale field trials to assess the efficacy and determine field application rates of new molluscicide products for control of schistosomiasis.

WHO Living guideline: Drugs to prevent COVID-19
recommended

World Health Organization WHO (2021) C_WHO

Interim guidance 2 march 2021 Current use of drugs to prevent COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized trials of many different drugs are underway to inform practice. This first version of the Drugs to prevent COVID-19: A WHO living guideline contains new inform... more

External Link

A living WHO guideline on drugs for covid-19
recommended

Rochweg, B.; et al. (2021) CC

BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379 Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE... more

External Link

National Guidelines for Diabetic Eye Care

Ministry of Health Malawi (2021) CC

Diabetes mellitus (DM) is a global epidemic with significant morbidity. Diabetic retinopathy (DR) is the specific microvascular complication of DM and affects 1 in 3 persons with DM. DR remains a leading cause of vision loss in working adult populations. Patients with severe levels of DR are report... more

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the Eur

Marx, N.; Federici, M.; Schütt, K. et al. European Heart Journal (2023) CC

Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f... more

External Link

2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association

Kleindorfer, .O.; Towfighi, A.; Chaturvedi, S. et al. American Heart Association (2021) CC

Each year, ≈795 000 individuals in the United States experience a stroke, of which 87% (690 000) are ischemic and 185 000 are recurrent.1 Approximately 240 000 individuals experience a transient ischemic attack (TIA) each year.2 The risk of recurrent stroke or TIA is high but can be mitiga... more

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

Reducing surgical site infections in low-income and middle-income countries (FALCON): a pragmatic, multicentre, stratified, randomised controlled trial

Biccard, B.M.; V. Msosa, A.L Samateh et al. TheLancet (2021) CC

Surgical site infection (SSI) is the most common postoperative complication worldwide. WHO guidelines to prevent SSI recommend alcoholic chlorhexidine skin preparation and fascial closure using triclosan-coated sutures, but called for assessment of both interventions in low-resource settings. This s... more

Download (242)

View PDF (401)

Optimized Supportive Care for Ebola Virus Disease
recommended

World Health Organization WHO (2019) C_WHO

Clinical management standard operating procedures. Ebola virus disease (EVD) is a life-threatening multisystem illness associated with fever and gastrointestinal (GI) symptoms that frequently leads to hypovolaemia, metabolic acidosis, hypoglycaemia, and multi-organ failure. The prolonged 2013–201... more

Position statement on endoscopic lung volume reduction in South Africa: 2022 update

Koegelenberg, C.F.; Van Zyl-Smit, R.N.; Dheda, K. et al. African Journal of Thoracic and Critical Care Medicine (2022) CC

The article from the African Journal of Thoracic and Critical Care Medicine provides updated guidelines on endoscopic lung volume reduction (ELVR) for treating advanced emphysema, a severe form of chronic obstructive pulmonary disease (COPD), which is prevalent in South Africa and other low- and mid... more

Measurement properties and interpretation of three shortened versions of the asthma control questionnaire

Juniper, E. F.; Svensson, K.; Mörk, A-C.; et al. Respiratory Medicine (2005) 99, 553–558 (2005) CC2

The Asthma Control Questionnaire (ACQ)1 was developed and validated to measure the primary clinical goal of asthma management as identified by international guidelines. They indicate that to achieve good control, treatment should minimise day and night time symptoms, activity limitation, airway narr... more

Download (67)

View PDF (51)

Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes

Park, J.J. Diabetes & Metabolism Journal (2021) CC

The cardiovascular disease continuum begins with risk factors such as diabetes mellitus (DM), progresses to vasculopathy and myocardial dysfunction, and finally ends with cardiovascular death. Diabetes is associated with a 2- to 4-fold increased risk for heart failure (HF). Moreover, HF patients wit... more

WHO Living guideline: Drugs to prevent COVID-19 recommended

A living WHO guideline on drugs for covid-19 recommended

Optimized Supportive Care for Ebola Virus Disease recommended

WHO Living guideline: Drugs to prevent COVID-19
recommended

A living WHO guideline on drugs for covid-19
recommended

Optimized Supportive Care for Ebola Virus Disease
recommended